Rekombinanter IL2RA (Daclizumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter IL2RA (Daclizumab Biosimilar) Antikörper (ABIN7795104)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Daclizumab Biosimilar, CD25 Monoclonal Antibody
-
Produktmerkmale
- Daclizumab Biosimilar uses the same protein sequences as the therapeutic antibody daclizumab. Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90 % ) and murine (10 %) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human CD25
-
-
anti-IL2RA (Daclizumab Biosimilar) antibody
Reaktivität: Human, Cynomolgus, Rhesusaffen FACS, BR Wirt: Kaninchen Chimeric unconjugated Recombinant Antibody
anti-IL2RA (Daclizumab Biosimilar) antibodyReaktivität: Human, Cynomolgus, Rhesusaffen FACS, BR Wirt: Human Monoclonal unconjugated Recombinant Antibody
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- IL2RA (Daclizumab Biosimilar)
-
Andere Bezeichnung
- Daclizumab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-
